These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Surfactant protein-A deficiency in a primate model of bronchopulmonary dysplasia. King RJ; Coalson JJ; deLemos RA; Gerstmann DR; Seidner SR Am J Respir Crit Care Med; 1995 Jun; 151(6):1989-97. PubMed ID: 7767549 [TBL] [Abstract][Full Text] [Related]
25. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Günther A; Mosavi P; Ruppert C; Heinemann S; Temmesfeld B; Velcovsky HG; Morr H; Grimminger F; Walmrath D; Seeger W Thromb Haemost; 2000 Jun; 83(6):853-60. PubMed ID: 10896238 [TBL] [Abstract][Full Text] [Related]
27. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459 [TBL] [Abstract][Full Text] [Related]
28. Changes in pulmonary tissue structure and KL-6/MUC1 expression in a newborn rat model of hyperoxia-induced bronchopulmonary dysplasia. Zhu Y; Fu J; You K; Jin L; Wang M; Lu D; Xue X Exp Lung Res; 2013 Dec; 39(10):417-26. PubMed ID: 24298937 [TBL] [Abstract][Full Text] [Related]
29. Diffuse alveolar damage in the evolution of bronchopulmonary dysplasia in the baboon. Coalson JJ; Kuehl TJ; Prihoda TJ; deLemos RA Pediatr Res; 1988 Sep; 24(3):357-66. PubMed ID: 3211622 [TBL] [Abstract][Full Text] [Related]
30. Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Bagchi A; Viscardi RM; Taciak V; Ensor JE; McCrea KA; Hasday JD Pediatr Res; 1994 Aug; 36(2):244-52. PubMed ID: 7970941 [TBL] [Abstract][Full Text] [Related]
31. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071 [TBL] [Abstract][Full Text] [Related]
32. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. Yamamoto K; Loskutoff DJ J Clin Invest; 1996 Jun; 97(11):2440-51. PubMed ID: 8647936 [TBL] [Abstract][Full Text] [Related]
33. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. ter Horst SA; Wagenaar GT; de Boer E; van Gastelen MA; Meijers JC; Biemond BJ; Poorthuis BJ; Walther FJ J Appl Physiol (1985); 2004 Nov; 97(5):2014-9. PubMed ID: 15208286 [TBL] [Abstract][Full Text] [Related]
34. Abnormalities of pathways of fibrin turnover in the human pleural space. Idell S; Girard W; Koenig KB; McLarty J; Fair DS Am Rev Respir Dis; 1991 Jul; 144(1):187-94. PubMed ID: 2064128 [TBL] [Abstract][Full Text] [Related]
35. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. Olman MA; Mackman N; Gladson CL; Moser KM; Loskutoff DJ J Clin Invest; 1995 Sep; 96(3):1621-30. PubMed ID: 7544811 [TBL] [Abstract][Full Text] [Related]
36. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]